Kalaitzidis RG, Karasavvidou DP, Tatsioni A, Pappas K, Katatsis G, Liontos A, Elisaf MS. Albuminuria as a marker of arterial stiffness in chronic kidney disease patients. World J Nephrol 2015; 4(3): 406-414 [PMID: 26167465 DOI: 10.5527/wjn.v4.i3.406]
Corresponding Author of This Article
Moses S Elisaf, MD, FASA, FRSH, Professor, Department of Internal Medicine, Medical School, University of Ioannina, Epirus, 45110 Ioannina, Greece. egepi@cc.uoi.gr
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Clinical Trial Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Nephrol. Jul 6, 2015; 4(3): 406-414 Published online Jul 6, 2015. doi: 10.5527/wjn.v4.i3.406
Albuminuria as a marker of arterial stiffness in chronic kidney disease patients
Rigas G Kalaitzidis, Despina P Karasavvidou, Athina Tatsioni, Kosmas Pappas, Giorgos Katatsis, Angelos Liontos, Moses S Elisaf
Rigas G Kalaitzidis, Despina P Karasavvidou, Kosmas Pappas, Giorgos Katatsis, Angelos Liontos, Moses S Elisaf, Outpatient Renal and Hypertension Clinic, University Hospital of Ioannina, 45110 Ioannina, Greece
Athina Tatsioni, Moses S Elisaf, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece
Author contributions: Kalaitzidis RG and Elisaf MS designed research; Karasavvidou DP, Pappas K, Katatsis G and Liontos A performed research; Tatsioni A analyzed data; Elisaf MS and Kalaitzidis RG wrote the paper.
Ethics approval statement: Our hospital Ethics Committee approved this study protocol with a registration identification number (AΔΑΒΛΓΦ46906Η-ΛΟΛ).
Informed consent statement: Informed consent was obtained from all patients.
Conflict-of-interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at Moses Elisaf [melisaf54@gmail.com, egepi@cc.uoi.gr]. Participants gave informed consent for data sharing even though are anonymized and the risk of identification is low.
Correspondence to: Moses S Elisaf, MD, FASA, FRSH, Professor, Department of Internal Medicine, Medical School, University of Ioannina, Epirus, 45110 Ioannina, Greece. egepi@cc.uoi.gr
Telephone: +30-265-1007509 Fax: +30-265-1007016
Received: November 4, 2014 Peer-review started: November 9, 2014 First decision: November 27, 2014 Revised: December 22, 2014 Accepted: April 8, 2015 Article in press: April 9, 2015 Published online: July 6, 2015 Processing time: 244 Days and 4 Hours
Core Tip
Core tip: Albuminuria heightened cardiovascular disease risk. Pulse wave velocity and augmentation index are markers of aortic stiffness (AS). However, whether severely increased albuminuria is a factor of AS elevation and its progressive deterioration in non-diabetic hypertensive patients treated with renin angiotensin aldosterone blockade agents (RAAS) has not be studied. In this study we aimed to access the association between albuminuria levels and AS, in chronic kidney disease (CKD) stage 1-2 non-diabetic patients with hypertension. All patients were already treated with RAAS blockade agents. Our findings demonstrate an independent association between AS indices and severely increased albuminuria in non-diabetic, hypertensive patients with CKD stages 1-2 treated with RAAS blockers.
